Sumitomo Pharma unveils new COURAGE & OPTYX data at AUA 2026

Highlights strong Vibegron results in older men & real-world prostate cancer insights

Merck reports breakthrough Phase 3 win for sac-TMT in endometrial cancer

Experts push for patient-centric healthcare at IHW Patient First Summit 2026

Healthcare leaders, policymakers, hospitals, and patient advocates discuss AI-driven healthcare, digital transformation, quality of life in cancer care

Merck posts mixed Q1 2026 results as blockbuster drugs drive growth

But acquisition charges drag earnings into loss

UICC report flags air pollution as major multi-cancer risk

The long-term exposure to fine particulate matter (PM2.5) increases overall cancer risk by 11%

ImmunityBio scores first Asian approval for ANKTIVA in Macau

The Macau authorization followed a regulatory review that considered prior decisions by both the US FDA) and the European Medicines Agency

ImmunityBio partners with Middle East giants to launch ANKTIVA for cancer patients

To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia

Pangea Laboratory teams with Gene Solutions to bring AI-driven cancer tests to US patients

Pangea will use its integrated validation platform and regulatory expertise to oversee analytical and clinical validation of Gene Solutions’ multi-omics technologies.

Bengaluru docs perform world’s first single-stage robotic heart bypass & prostate cancer surgery

Moderna & Merck study: mRNA therapy plus KEYTRUDA cut melanoma recurrence risk by half

The study evaluated patients with stage III/IV melanoma after complete tumor resection